xestoquinone has been researched along with p5091 in 1 studies
| Studies (xestoquinone) | Trials (xestoquinone) | Recent Studies (post-2010) (xestoquinone) | Studies (p5091) | Trials (p5091) | Recent Studies (post-2010) (p5091) |
|---|---|---|---|---|---|
| 16 | 0 | 4 | 24 | 0 | 23 |
| Protein | Taxonomy | xestoquinone (IC50) | p5091 (IC50) |
|---|---|---|---|
| Ubiquitin carboxyl-terminal hydrolase 7 | Homo sapiens (human) | 4.2 | |
| Ubiquitin carboxyl-terminal hydrolase 47 | Homo sapiens (human) | 4.3 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arsenault, P; Chen, L; Kumar, S; Mattern, M; Wang, F; Wang, H; Weinstock, J; Wu, J | 1 |
1 review(s) available for xestoquinone and p5091
| Article | Year |
|---|---|
Chemical Approaches to Intervening in Ubiquitin Specific Protease 7 (USP7) Function for Oncology and Immune Oncology Therapies.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Crystallography, X-Ray; Drug Evaluation, Preclinical; Enzyme Inhibitors; Humans; Molecular Targeted Therapy; Proteasome Inhibitors; Protein Conformation; Ubiquitin; Ubiquitin-Specific Peptidase 7 | 2018 |